Dipna Pharmachem Ltd vs Remus Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Dipna Pharmachem Ltd is ₹ 7.94 as of 30 Apr 15:30 . The P/E Ratio of Dipna Pharmachem Ltd is 0 as of March 2024 .The P/E Ratio of Remus Pharmaceuticals Ltd is 49.4 as of March 2024 . The Market Cap of Dipna Pharmachem Ltd is ₹ 0 crore as of March 2024 .The Market Cap of Remus Pharmaceuticals Ltd is ₹ 1016 crore as of March 2024 . The Dividend Payout of Dipna Pharmachem Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Remus Pharmaceuticals Ltd changed from 2.56 % on March 2023 to 4.44 % on March 2025 . This represents a CAGR of 20.15% over 3 years .

About Dipna Pharmachem Ltd

Dipan Pharmachem Limited was incorporated on July 19, 2011.
Subsequently, the Company name was changed to 'Dipna Pharmachem Private Limited' on March 29, 2012.
Later on, it was converted from Private Limited to Public Limited and the name of Company was changed to 'Dipna Pharmachem Limited' vide fresh Certificate of Incorporation issued by Registrar of Companies, Ahmedabad dated May 25, 2022. Dipna Pharmachem Limited is a trader, importer, and exporter in industrial Chemical and Pharmaceutical Raw materials, APIs, solvents, and Formulation since 2011.
Presently, its product portfolio comprises of 61 AIPs and AIPs intermediates such as Cephalosporins, Cardiovasculars, Anti - Bactaria, Quinolones, Veterinary, Anti - Virus, Anti - Inflammatory, Neuropsychiatry, Steroid Hormone, other etc.

About Remus Pharmaceuticals Ltd

Remus Pharmaceuticals Limited was originally incorporated as Remus Pharmaceuticals Private Limited' as a Private Limited Company, vide Certificate of Incorporation dated September 21, 2015, issued by the Assistant Registrar of Companies, Gujarat.
Subsequently, Company converted from a Private to Public and the name of the Company was changed to 'Remus Pharmaceuticals Limited' on January 06, 2023 by the Registrar of Companies, Ahmedabad. The Company is engaged in marketing & distribution of finished formulations of pharmaceutical drugs.
It deals in API (Active Pharmaceutical Ingredient), provide technical consultancy services to various distributors for preparation of reports on the dossiers of the products to be registered by them in various countries.
The Company deal in drug forms like Capsules, Cream, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nail Lacquer, Nasal Solution, Nasal Spray, Nebuliser, Ointment, Ophthalmic, Oral Gel, Oral Solution, Oral Suspension, Sachet, Suspension, Tablet.

FAQs for the comparison of Dipna Pharmachem Ltd and Remus Pharmaceuticals Ltd

Which company has a larger market capitalization, Dipna Pharmachem Ltd or Remus Pharmaceuticals Ltd?

Market cap of Dipna Pharmachem Ltd is 20 Cr while Market cap of Remus Pharmaceuticals Ltd is 807 Cr

What are the key factors driving the stock performance of Dipna Pharmachem Ltd and Remus Pharmaceuticals Ltd?

The stock performance of Dipna Pharmachem Ltd and Remus Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Dipna Pharmachem Ltd and Remus Pharmaceuticals Ltd?

As of May 3, 2026, the Dipna Pharmachem Ltd stock price is INR ₹7.94. On the other hand, Remus Pharmaceuticals Ltd stock price is INR ₹685.3.

How do dividend payouts of Dipna Pharmachem Ltd and Remus Pharmaceuticals Ltd compare?

To compare the dividend payouts of Dipna Pharmachem Ltd and Remus Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.